NASDAQ:TTHI - Transition Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$1.5248
Today's Range$1.5248 - $1.5248
52-Week Range$0.66 - $2.75
VolumeN/A
Average Volume70,238 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Receive TTHI News and Ratings via Email

Sign-up to receive the latest news and ratings for TTHI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:TTHI
CUSIPN/A
Phone+1-416-2607770

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions

What is Transition Therapeutics' stock symbol?

Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."

Has Transition Therapeutics been receiving favorable news coverage?

Media headlines about TTHI stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Transition Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.

How do I buy shares of Transition Therapeutics?

Shares of TTHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Transition Therapeutics' official website?

The official website for Transition Therapeutics is http://www.transitiontherapeutics.com/.

How can I contact Transition Therapeutics?

Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.


MarketBeat Community Rating for Transition Therapeutics (NASDAQ TTHI)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe TTHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel